JP2010539082A5 - - Google Patents

Download PDF

Info

Publication number
JP2010539082A5
JP2010539082A5 JP2010524063A JP2010524063A JP2010539082A5 JP 2010539082 A5 JP2010539082 A5 JP 2010539082A5 JP 2010524063 A JP2010524063 A JP 2010524063A JP 2010524063 A JP2010524063 A JP 2010524063A JP 2010539082 A5 JP2010539082 A5 JP 2010539082A5
Authority
JP
Japan
Prior art keywords
salt
complex according
cyclodextrin
complex
composition
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2010524063A
Other languages
English (en)
Japanese (ja)
Other versions
JP5474792B2 (ja
JP2010539082A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2008/056393 external-priority patent/WO2009035718A1/en
Publication of JP2010539082A publication Critical patent/JP2010539082A/ja
Publication of JP2010539082A5 publication Critical patent/JP2010539082A5/ja
Application granted granted Critical
Publication of JP5474792B2 publication Critical patent/JP5474792B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2010524063A 2007-09-10 2008-03-10 亜鉛結合部分を含むキナゾリンベースegfrインヒビターの酒石酸塩またはその複合体 Expired - Fee Related JP5474792B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US97105607P 2007-09-10 2007-09-10
US60/971,056 2007-09-10
PCT/US2008/056393 WO2009035718A1 (en) 2007-09-10 2008-03-10 Tartrate salts or complexes of quinazoline based egfr inhibitors containing a zinc binding moiety

Publications (3)

Publication Number Publication Date
JP2010539082A JP2010539082A (ja) 2010-12-16
JP2010539082A5 true JP2010539082A5 (enExample) 2011-03-24
JP5474792B2 JP5474792B2 (ja) 2014-04-16

Family

ID=40452375

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2010524063A Expired - Fee Related JP5474792B2 (ja) 2007-09-10 2008-03-10 亜鉛結合部分を含むキナゾリンベースegfrインヒビターの酒石酸塩またはその複合体

Country Status (7)

Country Link
US (3) US7846938B2 (enExample)
EP (1) EP2190287B1 (enExample)
JP (1) JP5474792B2 (enExample)
AU (1) AU2008299896B2 (enExample)
CA (1) CA2698944C (enExample)
ES (1) ES2526718T3 (enExample)
WO (1) WO2009035718A1 (enExample)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP5580592B2 (ja) 2006-09-11 2014-08-27 キュリス,インコーポレイテッド 亜鉛結合部分を含むキナゾリン系egfrインヒビター
CN101570516B (zh) * 2009-04-14 2011-01-05 重庆威尔德·浩瑞医药化工有限公司 一种制备4-(3-氯-4-氟苯基胺基)-7-甲氧基-6-[3-(4-吗啉基)丙氧基]喹唑啉的方法
CN102452988B (zh) * 2010-10-27 2016-01-27 中国科学院化学研究所 一种喹唑啉衍生物及其制备方法
EP2685980B1 (en) 2011-03-17 2017-12-06 The Trustees Of The University Of Pennsylvania Methods and use of bifunctional enzyme-building clamp-shaped molecules
WO2012125904A1 (en) 2011-03-17 2012-09-20 The Trustees Of The University Of Pennsylvania Mutation mimicking compounds that bind to the kinase domain of egfr
US20140229256A1 (en) 2013-02-11 2014-08-14 Solutran Product substantiation using approved product list system and method
CN102276500A (zh) * 2011-05-05 2011-12-14 西安交通大学 水杨酰胺类抗肿瘤化合物及其合成方法和用途
CN103906732A (zh) * 2011-10-28 2014-07-02 株式会社钟根堂 用作hdac抑制剂的异羟肟酸酯衍生物以及包含所述衍生物的药物组合物
WO2013159698A1 (zh) * 2012-04-26 2013-10-31 深圳信立泰药业股份有限公司 稠环喹唑啉羟肟酸类化合物及其作为抗肿瘤药物的应用
CN102898315B (zh) * 2012-11-05 2015-01-28 上海毕得医药科技有限公司 3-乙炔基-4-氟苯胺的制备方法
US10552861B2 (en) 2013-02-11 2020-02-04 Solutran, Inc. Dual redemption path with shared benefits system and method
MX2017001818A (es) 2014-08-08 2017-05-30 Forsight Vision4 Inc Formulaciones estables y solubles de inhibidores de receptor de quinasa tirosina y metodos de preparacion de los mismos.
CN105693630B (zh) * 2016-03-10 2018-02-16 田静 一种吉非替尼中间体的制备方法
WO2021044430A1 (en) * 2019-09-08 2021-03-11 Hadasit Medical Research Services And Development Ltd. Anti-fibrotic compounds and use thereof
US12100049B2 (en) 2020-06-05 2024-09-24 Soltran, LLC Filtered POS processing of services
CN116710448B (zh) * 2021-01-20 2025-05-16 莱托克斯有限公司 被保护的hdac(组蛋白脱乙酰酶)抑制剂
US12530346B2 (en) 2021-12-24 2026-01-20 Solutran, LLC Data transmission filtering through a customized filter list

Family Cites Families (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5369108A (en) 1991-10-04 1994-11-29 Sloan-Kettering Institute For Cancer Research Potent inducers of terminal differentiation and methods of use thereof
AU661533B2 (en) 1992-01-20 1995-07-27 Astrazeneca Ab Quinazoline derivatives
EP0626373B1 (en) * 1993-05-26 1998-12-23 Sumitomo Pharmaceuticals Company, Limited Quinazolinone derivatives
GB9508537D0 (en) 1995-04-27 1995-06-14 Zeneca Ltd Quinazoline derivatives
GB9508538D0 (en) * 1995-04-27 1995-06-14 Zeneca Ltd Quinazoline derivatives
US5747498A (en) 1996-05-28 1998-05-05 Pfizer Inc. Alkynyl and azido-substituted 4-anilinoquinazolines
JP4471404B2 (ja) 1996-02-13 2010-06-02 アストラゼネカ ユーケイ リミテッド Vegfインヒビターとしてのキナゾリン誘導体
US6777217B1 (en) 1996-03-26 2004-08-17 President And Fellows Of Harvard College Histone deacetylases, and uses related thereto
DK1553097T3 (da) 1999-02-10 2010-12-13 Astrazeneca Ab Quinazolinderivat som angiogeneseinhibitor og mellemprodukter dertil
US7230000B1 (en) * 1999-10-27 2007-06-12 Cytokinetics, Incorporated Methods and compositions utilizing quinazolinones
UA74803C2 (uk) 1999-11-11 2006-02-15 Осі Фармасьютікалз, Інк. Стійкий поліморф гідрохлориду n-(3-етинілфеніл)-6,7-біс(2-метоксіетокси)-4-хіназолінаміну, спосіб його одержання (варіанти) та фармацевтичне застосування
TWI310684B (en) * 2000-03-27 2009-06-11 Bristol Myers Squibb Co Synergistic pharmaceutical kits for treating cancer
ATE340165T1 (de) 2001-02-26 2006-10-15 Univ Mcgill Kombi-moleküle, welche eine inhibierende wirkung auf die signalübertragung und dna-schädigende eigenschaften haben
AU2003257666A1 (en) 2002-08-23 2004-03-11 Kirin Beer Kabushiki Kaisha COMPOUND HAVING TGFss INHIBITORY ACTIVITY AND MEDICINAL COMPOSITION CONTAINING THE SAME
US7250514B1 (en) 2002-10-21 2007-07-31 Takeda San Diego, Inc. Histone deacetylase inhibitors
JP2006515871A (ja) * 2003-01-23 2006-06-08 ティー.ケイ. シグナル リミテッド 上皮増殖因子受容体チロシンキナーゼの不可逆阻害剤ならびにその使用
PE20040945A1 (es) * 2003-02-05 2004-12-14 Warner Lambert Co Preparacion de quinazolinas substituidas
EP1670786A1 (en) * 2003-09-25 2006-06-21 Astrazeneca AB Quinazoline derivatives
GB0322409D0 (en) * 2003-09-25 2003-10-29 Astrazeneca Ab Quinazoline derivatives
WO2005097134A2 (en) 2004-03-31 2005-10-20 The Scripps Research Institute Quinazoline based protein kinase inhibitors
EP2502649A1 (en) 2005-02-03 2012-09-26 TopoTarget UK Limited Combination therapy using HDAC inhibitors and erlotinib for treating cancer
BRPI0607537A2 (pt) * 2005-04-12 2009-09-15 Elan Pharma Int Ltd formulações de derivado de quinazolina nanoparticulado
TW200718689A (en) 2005-04-14 2007-05-16 Chiron Corp 2-Amino-quinazolin-5-ones
ITMI20050729A1 (it) * 2005-04-22 2006-10-23 Endura Spa Nuova formulazione biologicamente attiva
WO2007131364A1 (en) 2006-05-16 2007-11-22 Mcgill University Hybrid molecules having mixed vitamin d receptor agonism and histone deacetylase inhibitory properties
US7547781B2 (en) 2006-09-11 2009-06-16 Curis, Inc. Quinazoline based EGFR inhibitors containing a zinc binding moiety
CA2662937A1 (en) * 2006-09-11 2008-03-20 Curis, Inc. Multi-functional small molecules as anti-proliferative agents
JP5580592B2 (ja) 2006-09-11 2014-08-27 キュリス,インコーポレイテッド 亜鉛結合部分を含むキナゾリン系egfrインヒビター
EP2061469B8 (en) 2006-09-11 2014-02-26 Curis, Inc. Quinazoline based egfr inhibitors
DK2343286T3 (en) 2006-10-28 2015-04-13 Methylgene Inc Dibenzo [b, f] [1,4] oxazepine derivatives as inhibitors of histone deacetylase
US8119616B2 (en) 2007-09-10 2012-02-21 Curis, Inc. Formulation of quinazoline based EGFR inhibitors containing a zinc binding moiety

Similar Documents

Publication Publication Date Title
JP2010539082A5 (enExample)
JP2020511467A5 (enExample)
JP2011511073A5 (enExample)
JP5852678B2 (ja) 抗腫瘍剤の効果増強剤
JP2012505916A5 (enExample)
JP2010523476A5 (enExample)
JP2009533482A5 (enExample)
JP2017509586A5 (enExample)
JP2013537203A5 (enExample)
JP2012506381A5 (enExample)
JP2014512356A5 (enExample)
JP2005500300A5 (enExample)
JP2013189456A5 (enExample)
JP2010526814A5 (enExample)
JP2017525730A5 (enExample)
JP2015508103A5 (enExample)
JP2014527042A5 (enExample)
JP2010540556A5 (enExample)
JP2019515026A5 (enExample)
JP2012526766A5 (enExample)
JP2012180344A5 (enExample)
JP2017530171A5 (enExample)
JP2015512943A5 (enExample)
JP2011510028A5 (enExample)
HRP20160545T1 (hr) Inhibitor fosfoinozitid 3-kinaze sa dijelom koji veže cink